Unraveling the Potential of IGHV1-18 as a Drug Target and Biomarker

Target Name: IGHV1-18

NCBI ID: G28468

IGHV1-18

Other Name(s): immunoglobulin heavy variable 1-18 | IGHV118 | Immunoglobulin heavy variable 1-18

Unraveling the Potential of IGHV1-18 as a Drug Target and Biomarker

Introduction

Immunoglobulin heavy variable 1-18 (IGHV1-18) is a single-chain variable region antibody that plays a crucial role in various physiological processes in the human body. It is one of the five classes of antibodies produced by B cells, along with IgG , IgA, IgM, IgE, and IgG subtypes. IGHV1-18 is characterized by its long variable region, which contains several constant and variable regions that give it unique structural features.

Recent studies have identified IGHV1-18 as a potential drug target and biomarker for various diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. In this article, we will delve into the research on IGHV1-18 and its potential applications as a drug target and biomarker.

Potential Drug Target

IGHV1-18 is a potential drug target due to its unique structure and function. Its long variable region allows for the production of a diverse range of antibody subtypes with different effector functions. IGHV1-18 can be modified to target various molecules in the body, making it an attractive candidate for targeting diseases caused by the overproduction or dysfunction of antibodies.

One of the promising aspects of IGHV1-18 is its ability to interact with ligand molecules. Its long variable region contains several regions that can form chemical bonds with other molecules, such as small molecules, peptides, or even other antibodies. This interactivity suggests that IGHV1-18 could be a useful anchor for targeting diseases caused by the misfolding or dysfunction of antibodies.

IGHV1-18 has also been shown to interact with various cellular signaling pathways, including the T cell receptor signaling pathway. This interaction suggests that IGHV1-18 may play a role in modulating the immune response and may be a useful target for diseases associated with inflammation or immune dysregulation.

Potential Biomarkers

IGHV1-18 has also been identified as a potential biomarker for various diseases. Its long variable region allows for the production of a diverse range of antibody subtypes with different effector functions, which could be used as biomarkers for disease diagnosis or monitoring.

One of the most promising applications of IGHV1-18 as a biomarker is its potential to detect cancer biomarkers in early stages. IGHV1-18 has been shown to have a low sensitivity for the detection of cancer biomarkers, but its high specificity makes it a promising candidate for cancer detection.

IGHV1-18 has also been used as a biomarker for Assessing the efficacy of anti-inflammatory therapies. Its ability to interact with ligand molecules and modulate the immune response suggests that it may be a useful marker for evaluating the efficacy of anti-inflammatory therapies.

Conclusion

In conclusion, IGHV1-18 is a promising candidate as a drug target and biomarker for various diseases. Its unique structure and function make it an attractive target for targeting diseases caused by the overproduction or dysfunction of antibodies. As further research is conducted, IGHV1- 18 is likely to prove to be a valuable tool for the diagnosis and treatment of a variety of diseases.

Protein Name: Immunoglobulin Heavy Variable 1-18

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV1-18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV1-18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets